Corporate Profile
CinCor is a clinical-stage biopharmaceutical company with a mission to dramatically improve the treatment paradigm for patients suffering from hypertension and other cardio-renal diseases. Its lead asset, baxdrostat (CIN-107), is a first-in-class, highly selective oral small molecule aldosterone synthase inhibitor, which is in clinical development for hypertension and other cardio-renal diseases.
